Wei Kang Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wei Kang Lim has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Alfonso Fasano
Department of Biomedical Sciences Humanitas University Milan Italy
3 shared publications - Carolina Gorodetsky
Division of Neurology, the Hospital for Sick Children, Toronto, Ontario, Canada
3 shared publications - Choong Yi Fong
Division of Paediatric Neurology, Department of Paediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
3 shared publications George M. Ibrahim
Division of Neurosurgery The Hospital for Sick Children Toronto Ontario Canada
2 shared publicationsLai Choo Ong
2 shared publicationsPei Lin Lua
2 shared publications
Latest Publications
- Open Access
- 22 September 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (3) , 774-778
Anticholinergic Burden and Botulinum Toxin Needs after Deep Brain Stimulation in Adult and Pediatric Patients with Dystonia
Background: Anticholinergic medications and botulinum neurotoxin injections are established treatments for dystonia, yet they carry potential side effects and practical challenges. Deep brain stimulation (DBS) is offered in case of poor response to these approaches. Objectives: To assess the need for anticholinergic medications and botulinum neurotoxin injections in adult and pediatric patients at two specialized Canadian centers before and after DBS over the past 10 years. Methods: 58 patients were included analyzing data before, 6 and 12 months after DBS. Clinical assessment included the Toronto Western Spasmodic Torticollis Rating Scale and Fahn‐Marsden Dystonia Rating Scale. Anticholinergic burden was determined by the Anticholinergic Drug Scale (ADS). Results: Severity of cervical dystonia and ADS scores reduction were statistically significant after DBS. Anticholinergic medication and Botulinum Neurotoxin injections were discontinued a year after surgery in 28.8% and 72.4% of the patients, respectively. Conclusion: Simplification of anti‐dystonia treatments is another added benefit of DBS.
- 22 September 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (3) , 774-778
Open AccessAnticholinergic Burden and Botulinum Toxin Needs after Deep Brain Stimulation in Adult and Pediatric Patients with Dystonia
Background: Anticholinergic medications and botulinum neurotoxin injections are established treatments for dystonia, yet they carry potential side effects and practical challenges. Deep brain stimulation (DBS) is offered in case of poor response to these approaches. Objectives: To assess the need for anticholinergic medications and botulinum neurotoxin injections in adult and pediatric patients at two specialized Canadian centers before and after DBS over the past 10 years. Methods: 58 patients were included analyzing data before, 6 and 12 months after DBS. Clinical assessment included the Toronto Western Spasmodic Torticollis Rating Scale and Fahn‐Marsden Dystonia Rating Scale. Anticholinergic burden was determined by the Anticholinergic Drug Scale (ADS). Results: Severity of cervical dystonia and ADS scores reduction were statistically significant after DBS. Anticholinergic medication and Botulinum Neurotoxin injections were discontinued a year after surgery in 28.8% and 72.4% of the patients, respectively. Conclusion: Simplification of anti‐dystonia treatments is another added benefit of DBS.
- Open Access
- 3 July 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (12) , 2375-2378
Deep Brain Stimulation in a Child with Aicardi‐Goutières Syndrome‐7 ( AGS7 ): A Case Report and Literature Review
- 3 July 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (12) , 2375-2378
Open AccessDeep Brain Stimulation in a Child with Aicardi‐Goutières Syndrome‐7 ( AGS7 ): A Case Report and Literature Review
- Open Access
- 17 June 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (11) , 2012-2014
Levodopa‐Responsive Dystonia Secondary to CTNNB1 Neurodevelopmental Disorder
- 17 June 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (11) , 2012-2014
Open AccessLevodopa‐Responsive Dystonia Secondary to CTNNB1 Neurodevelopmental Disorder
- 1 June 2019
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 64, 11-14
Extensive intracranial haemorrhage as a complication of acute lymphoblastic leukaemia with hyperleukocytosis
- 1 June 2019
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 64, 11-14
Extensive intracranial haemorrhage as a complication of acute lymphoblastic leukaemia with hyperleukocytosis
- 1 October 2017
- Published by Elsevier in Epilepsy & Behavior
- Vol. 75, 6-12
Provision of sudden unexpected death in epilepsy (SUDEP) information among Malaysian parents of children with epilepsy
- 1 October 2017
- Published by Elsevier in Epilepsy & Behavior
- Vol. 75, 6-12
Provision of sudden unexpected death in epilepsy (SUDEP) information among Malaysian parents of children with epilepsy
- 23 November 2016
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 36, 73-75
Mild encephalitis/encephalopathy with reversible splenial lesion (MERS) due to dengue virus
- 23 November 2016
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 36, 73-75
Mild encephalitis/encephalopathy with reversible splenial lesion (MERS) due to dengue virus